RBR-8ykm72j招募中2 期
Pilot phase II randomized, placebo-controlled clinical trial for the prevention and progression of SARS-CoV-2 infection of subjects and patients using a supplement treatment with LCT
onza Consumer Health Inc.0 个研究点开始时间: 2021年4月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 85Y（—）
入选标准
- •Cohort 1, males and females between 55 years and 85 years of age; history of close contact (cohabit) with a family member or a person newly diagnosed with SARS-CoV-2 infection; negative RT-PCR COVID-19 test on the screening and prior to start treatment .
- •Cohort 2, males and females between 18 years and 85 years of age;confirmed virology diagnostic of COVID-19; asymptomatic ou mild COVID 19 pneumonia.
排除标准
- •Females of childbearing potential who are pregnant, lactating, or who have not adhered to an adequate contraception method from at least 30 days prior to study entry and who do not plan to do so for at least 1 month post last supplementation;Patients that are doing hormonal replacement therapy; severe COVID-19 pneumonia according to CDC criteria associated with CT Severe Illness Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ; positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies; known or suspected alcohol or drug abuse within the past 6 months prior to screening,participation in another experimental protocol and/or receipt of any investigational products within the past 3 months prior to screening;treatment with immunosuppressive cytotoxic therapies (e.g., chemotherapy drugs or radiation) in the past 6 months prior to screening;patients unable to sign the inform consent to participate into the study;
- •History of any other acute or uncontrolled chronic illness (including, hypertension, cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders) that is not on medication regimen for at least the past 6 months, or use of medication or supplements that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety and tolerability of the study drug such as ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs)
研究者
相似试验
招募中
1 期
The Clinical Study of Yiqijiedu compound combined with anti-PD-1 antibody in the treatment of non-small cell lung cancer patients with chemotherapy resistanceITMCTR2100004241ongHua Hospital, Shanghai University of Traditional Chinese Medicine
已完成
2 期
Phase II, randomized, placebo-controlled study of docetaxel in combination with a mixed 20 peptides vaccine in patients with castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancerJPRN-UMIN000011028Research Center for Innovative Cancer Therapy, Kurume University School of Medicine46
进行中（未招募）
1 期
A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer's Disease DementiaCTIS2023-504017-79-00Merck Sharp & Dohme LLC408
进行中（未招募）
2 期
Phase 2a/2b Study of MK-1942 in Participants with Alzheimer's Disease dementiaAlzheimer's Disease DementiaJPRN-jRCT2031220532Tanaka Yoshiyuki408
已完成
不适用
A Phase II Randomized, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus (Ridaforolimus) in Men With Asymptomatic, Metastatic Castrate-resistant Prostate Cancer-C61 Malignant neoplasm of prostateMalignant neoplasm of prostateC61PER-142-08MERCK SHARP & DOHME PERU S.R.L.,